Cravens & Co Advisors’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Cravens & Co Advisors’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,023	Closed	-$390K	–	71
2025 Q4	$390K	Buy	+15,023	New	+$370K	0.26%	47

Other funds holding THNR

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $117M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cravens & Co Advisors's THNR Position: Q1 2026 in Review

Cravens & Co Advisors sold out of Amplify Weight Loss Drug & Treatment ETF (THNR) in Q1 2026, closing a stake of 15,023 shares — an estimated $390K sold.

Cravens & Co Advisors first reported a position in THNR in Q4 2025 and held it in 1 quarter. The position peaked at $390K in Q4 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q1 2026.

Cravens & Co Advisors reported no remaining Amplify Weight Loss Drug & Treatment ETF position as of Q1 2026 after selling out during the quarter.
Cravens & Co Advisors sold 15,023 Amplify Weight Loss Drug & Treatment ETF shares in Q1 2026, an estimated $390K.
Cravens & Co Advisors first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q4 2025 and held it in 1 quarter.
Cravens & Co Advisors's Amplify Weight Loss Drug & Treatment ETF position peaked at $390K in Q4 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.